Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Cross Above Two Hundred Day Moving Average - What's Next?

Key Points

• Bayer shares crossed above their 200-day moving average, reaching $12.75 and closing at $12.69, up 3.2% in trading volume of approximately 776,000 shares.
• Analyst sentiment improved, with Zacks Research upgrading the stock to “strong buy” and Deutsche Bank moving it to “buy.” The consensus rating is “Buy,” including two Strong Buy, five Buy and one Hold ratings.
• Bayer exceeded quarterly expectations, reporting $0.29 in EPS versus $0.23 expected and revenue of $12.53 billion versus $12.31 billion forecast. The company provided fiscal 2026 EPS guidance of $1.200–$1.346.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $12.49 and traded as high as $12.75. Bayer Aktiengesellschaft shares last traded at $12.69, with a volume of 775,721 shares.

Analysts Set New Price Targets

A number of research firms recently issued reports on BAYRY. Zacks Research raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Thursday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy".

Bayer Aktiengesellschaft Trading Up 3.2%

The stock has a market cap of $49.87 billion, a price-to-earnings ratio of -24.88, a PEG ratio of 1.86 and a beta of 0.57. The company has a quick ratio of 0.67, a current ratio of 1.04 and a debt-to-equity ratio of 1.05. The business's 50 day simple moving average is $13.52 and its 200 day simple moving average is $12.49.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, research analysts expect that Bayer Aktiengesellschaft will post 1.27 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.